Combined effects of klotho and soluble CD40 ligand on A549 lung cancer cells

Oncology Reports

Volumn 25, Issue 5, 2011, Pages 1465-1472

  Wang, Xueli ^a   Chen, Bo ^a   Xu, Wei ^a   Liu, Shifeng ^a   Zhao, Weihong ^a   Wu, Jianqing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Combined therapy; Gene therapy; Klotho; Lung neoplasm; sCD40L

Indexed keywords

CD40 LIGAND; KLOTHO PROTEIN; PROTEIN BAX; PROTEIN BCL 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE PHASE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CD40 LIGAND; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONIDASE; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 79953044634     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1178     Document Type: Article

References (40)

1. Berhoune M, Banu E, Scotte F, Oudard S and Bonun B: Therapeutic strategy for treatment of metastatic non-small cell lung cancer. Ann Pharmacother 42: 1640-1652, 2008.
2. Kyung-sun H, Won-Kyung C, Jinsang Y, et al: Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice. BMC Cancer 5: 51-57, 2005.
3. Di Cristofano A, De Acetis M and Koff A: PTEN and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Gene 27: 2222-2241, 2001.
4. Kuro-o M, Matsumura Y, Aizawa H, et al: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390: 45-51, 1997. (Pubitemid 27494749)
5. Min D, Panoskaltsis-Mortari A, Kuro-o M, Hollander GA, Blazar BR and Weinberg KI: Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging. Blood 109: 2529-2537, 2007. (Pubitemid 46425898)
6. Kawaguchi H, Manabe N, Miyaura C, Chikuda H, Nakamura K and Kuro-o M: Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. J Clin Invest 1044: 229-237, 1999.
7. Matsumura Y, Aizawa H, Shiraki-Iida T, et al: Identification of the human klotho gene and its two transcripts encoding membrane secreted klotho protein. Biochem Biophy Res Commun 243: 626-630, 1998. (Pubitemid 28412578)
8. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A and Rosenblatt KP: Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281: 6120-6123, 2006. (Pubitemid 43847540)
9. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P and McGuinness OP: Suppression of aging in mice by the hormone Klotho. Science 309: 1829-1393, 2005.
10. Wolf I, Levanon S, Bose S, et al: Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene 292: 1-12, 2008.
11. Liu H, Fergusson MM, Castilho RM, Liu J, Cao L, Chen J and Malide D: Augmented Wnt signaling in a mammalian model of accelerated aging. Science 317: 803-806, 2007. (Pubitemid 47257917)
12. Lee J, Jeong DJ, Kim JS, et al: The anti-aging gene KLOTHO is a novel target for epigenetic silencing in human cervical carcinoma. Mol Cancer 9: 109, 2010.
13. Chen B, Wang XL, Zhao WH and Wu JQ: Klotho inhibits growth and promotes apoptosis in human lung cancer cell line A549. J Exp Clin Cancer Res 29: 99, 2010.
14. Berwelt-Baildon MS, Vonderheide RH, Maecker B, et al: Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cell as antigen-presenting cells: potential for clinical application. Blood 99: 3319-3325, 2002. (Pubitemid 34525313)
15. Gordon J and Pound JD: CD40 and its ligand: central players in B lymphocyte survival, grown and differentiation. Blood Rev 9: 53-56, 1995.
16. Grewal IS and Flavell RA: The CD40 ligand: at the center of the immune universe? Immunology 16: 59-70, 1997.
17. Tong AW and Stone MJ: Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 10: 1-13, 2007.
18. Loskog AS and Eliopoulos AG: The Janus faces of CD40 in cancer. Semin Immunol 21: 301-307, 2009.
19. Johnson PW, Watt SM, Betts DR, Davies D, Jordan S, Norton AJ and Lister TA: Isolated follicular lymphoma cell are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. Blood 82: 1848-1857, 1993.
20. Clod K, Asgari Z, Younes A, Palmer JL, Cabanillas F, Carbone A, Andreeff M and Younes A: Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance. Cancer 94: 1-5, 2002. (Pubitemid 34049035)
21. Yamada M, Shiroko T and Kawaguchi Y: CD40-CD40 lidand (CD154) engagement is required but not sufficient for modulating MHC class I, ICAM-I and Fas expression and proliferation of human non-small cell lung tumors. Int J Cancer 92: 589-599, 2001. (Pubitemid 32319435)
22. Noguchi M, Imaizumi K and Kawabe T: Indution of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer. Cancer Gene Ther 8: 421-429, 2001. (Pubitemid 32757959)
23. Wu JQ, Zhao WH, Li Y, Zhu B and Yin KS: Adeno-associated virus mediated gene transfer into lung cancer cells promoting CD40 ligand-based immunotherapy. Virology 368: 309-316, 2007. (Pubitemid 350016226)
24. Tong AW, Papayoti MH, Netto G, Armstrong DT, Ordonez G, Lawson JM and Stone MJ: Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 7: 691-703, 2001. (Pubitemid 32707996)
25. Eliopoulos AG, Dawson CW, Mosialos G, et al: CD40-induced growth inhibition in epithelial cell is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 13: 2243-2254, 1996. (Pubitemid 26411575)
26. Schlienger K, Chu CS, Woo EY, et al: TRANCE-and CD40 ligand-matured dendritic cells reveal MHC I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 9: 1517-1527, 2003. (Pubitemid 36418410)
27. Georgopoulos NT, Steele LP, Thomson MJ and Selby PJ: A novel mechanism of CD401-induced of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Differ 13: 1789-1801, 2006. (Pubitemid 44390865)
28. Chen WX, Chen YQ, Zou XS, et al: The mechanism of inhibiting lung cancer cell by CD40 ligand activations. Pract J Cancer 24: 132-134, 2009.
29. Mulin BH, Wilson SG, Fislam FM, Calautti M, Dick IM, Devine A and Prince RL: Klotho gene polymorphisms are associated with osteocalcin levels but not bone density of aged postmenopausal women. Calcif Tissue Int 77: 145-151, 2005. (Pubitemid 41569744)
30. Yamada Y, Ando F, Niino N and Shimokata H: Association of polymorphisms of the androgen receptor and klotho gene with bone mineral density in Japanese women. J Mol Med 83: 50-57, 2005. (Pubitemid 40169496)
31. Arking DE, Becker DM, Yanek LR, Fallin D, Judge DP, Moy TF, Bbecker LC and Dietz HC: KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet 72: 1154-1161, 2003. (Pubitemid 36530003)
32. Suga T, Kurabayashi M, Sando Y, et al: Disruption of the klotho gene cause pulmonary emphysema in mice. Defect in maintenance of pulmonary integrity during postnatal life. Am J Respir Cell Mol Biol 22: 26-33, 2000. (Pubitemid 30342956)
33. Cha SK, Ortega B, Kurosu H, Rosenblatt KP, Kuro-o M and Huang CL: Removal of sialic acid involving klotho causes cell-3 surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci USA 105: 9805-9810, 2008. (Pubitemid 352031381)
34. Wolf I, Laitman Y, Rubinek T, et al: Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin. Oncogene 29: 26-23, 2010.
35. Eliopoulos AG, Davies C, Knox PG, Gallagher NJ, Afford SC, Adams DH and Young LS: CD40 induces apoptosis in carcinoma cells through an activation of cytotoxic ligand. Mol Cell Biol 20: 5503-5515, 2000. (Pubitemid 30482887)
36. Ghamande S, Hylander BL, Oflazoglu E, Lele S, Fanslow W and Repasky EA: Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res 61: 7556-7562, 2001. (Pubitemid 32995048)
37. Hoffmann TK, Meidenbauer N, Muller-Berghaus J, Storkus WJ and Whiteside TL: Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells. J Immunother 24: 162-171, 2001. (Pubitemid 32183062)
38. Mazouz N, Ooms A, Moulin V, Van Meirvenne S, Uyttenhove C and Degiovanni G: CD40 triggering increases the efficiency of dendritic cells for antitumoral immunization. Cancer Immun 2: 2-10, 2002.
39. Li Q, Grover AG, Donald EJ, et al: Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the atitumor reactivity of tumor-primed lymph node cell. J Immunol 175: 1424-1432, 2005. (Pubitemid 41023041)
40. Arking DE, Krebsova A, Macek M, Macek M Sr, Macek M Jr, Aking A and Mian IS: Association of human aging with a functional variant of klotho. Proc Natl Acad Sci USA 99: 856-861, 2002. (Pubitemid 34106600)